Direct inhibition of RAS: Quest for the Holy Grail?
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
RAS GTPases (H-, K-, and N-RAS) are the most frequently mutated oncoprotein family in human cancer. However, the relatively smooth surface architecture of RAS and its picomolar affinity for nucleotide have given rise to the assumption that RAS is an “undruggable” target. Recent advancements in drug screening, molecular modeling, and a greater understanding of RAS function have led to a resurgence in efforts to pharmacologically target this challenging foe. This review focuses on the state of the art of RAS inhibition, the approaches taken to achieve this goal, and the challenges of translating these discoveries into viable therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 7×
“Insertion of Compound 12 into this pocket, which they named S-IIP, shifts the preference of nucleotide binding from GTP to GDP.(57) As with SML-8-73-1, Compound 12 is specific for the G12C mutation, and thus does not inhibit wild type or other oncogenic permutations of RAS.”
BackgroundInfluentialTargeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 3×
“3B).(5,30) KRAS mutations, in contrast, account for nearly 85% of all RAS mutations in human tumors, with nearly 100% of pancreatic ductal adenocarcinoma possessing mutant KRAS alleles.”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 8×
“This failure has led to the perception of RAS as “undruggable”.(5) Recent advances in drug discovery techniques, high throughput”
BackgroundInfluentialGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903 · cited 4×
“5C).57 Insertion of Compound 12 into this pocket, which they named S-IIP, shifts the preference of nucleotide binding from GTP to GDP.57 As with SML-8-73-1, Compound 12 is specific for the G12C mutation, and thus does not inhibit wild type or other oncogenic permutations of RAS.”
BackgroundInfluentialPhysiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867 · cited 4×
“5C).57 Insertion of Compound 12 into this pocket, which they named S-IIP, shifts the preference of nucleotide binding from GTP to GDP.57 As with SML-8-73-1, Compound 12 is specific for the G12C mutation, and thus does not inhibit wild type or other oncogenic permutations of RAS.”
BackgroundInfluentialRAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“KRAS mutations, in contrast, account for nearly 85% of all RAS mutations in human tumors, with nearly 100% of pancreatic ductal adenocarcinoma possessing mutant KRAS alleles.(5,24,30,31) N-RAS is found mutated in ~11% of cancers including melanoma and multiple myeloma.”
BackgroundBiochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Research works printed but not linked: 85
- Harvey, 1964, An unidentified virus which causes the rapid production of tumours in mice, Nature, 204, 1104, 10.1038/2041104b0 · DOI · Paper page
- Kirsten, 1967, Morphologic responses to a murine erythroblastosis virus, J. Natl. Cancer Inst., 39, 311
- Hall, 1983, Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1, Nature, 303, 396, 10.1038/303396a0 · DOI · Paper page
- Shimizu, 1983, Three human transforming genes are related to the viral ras oncogenes, Proc. Natl. Acad. Sci. U. S. A., 80, 2112, 10.1073/pnas.80.8.2112 · DOI · Paper page
- Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
- Hall, 2002, The structural basis for the transition from Ras-GTP to Ras-GDP, Proc. Natl. Acad. Sci. U. S. A., 99, 12138, 10.1073/pnas.192453199 · DOI · Paper page
- Milburn, 1990, Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins, Science, 247, 939, 10.1126/science.2406906 · DOI · Paper page
- Zhou, 2015, Ras nanoclusters: versatile lipid-based signaling platforms, Biochim. Biophys. Acta, 1853, 841, 10.1016/j.bbamcr.2014.09.008 · DOI · Paper page
- Parker, 2015, The ras-membrane interface: isoform-specific differences in the catalytic domain, Mol. Cancer Res., 13, 595, 10.1158/1541-7786.MCR-14-0535 · DOI · Paper page
- Abankwa, 2010, Ras membrane orientation and nanodomain localization generate isoform diversity, Proc. Natl. Acad. Sci. U. S. A., 107, 1130, 10.1073/pnas.0903907107 · DOI · Paper page
- Abankwa, 2008, A novel switch region regulates H-ras membrane orientation and signal output, EMBO J., 27, 727, 10.1038/emboj.2008.10 · DOI · Paper page
- Thapar, 2004, NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation, J. Mol. Biol., 343, 1391, 10.1016/j.jmb.2004.08.106 · DOI
- Dharmaiah, 2016, Structural basis of recognition of farnesylated and methylated KRAS4b by PDEdelta, Proc. Natl. Acad. Sci. U. S. A., 113, E6766, 10.1073/pnas.1615316113 · DOI · Paper page
- Hancock, 1989, All ras proteins are polyisoprenylated but only some are palmitoylated, Cell, 57, 1167, 10.1016/0092-8674(89)90054-8 · DOI · Paper page
- Choy, 1999, Endomembrane trafficking of Ras: the CAAX motif targets proteins to the ER and Golgi, Cell, 98, 69, 10.1016/S0092-8674(00)80607-8 · DOI · Paper page
- Hancock, 1990, A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane, Cell, 63, 133, 10.1016/0092-8674(90)90294-O · DOI · Paper page
- Hancock, 1991, A caax or a caal motif and a 2nd signal are sufficient for plasma-membrane targeting of ras proteins, EMBO J., 10, 4033, 10.1002/j.1460-2075.1991.tb04979.x · DOI · Paper page
- Malliri, 2002, Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours, Nature, 417, 867, 10.1038/nature00848 · DOI · Paper page
- Bai, 2004, Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development, Cancer Res., 64, 8808, 10.1158/0008-5472.CAN-04-3143 · DOI · Paper page
- Gonzalez-Garcia, 2005, RaIGDS is required for tumor formation in a model of skin carcinoigenesis, Cancer Cell, 7, 219, 10.1016/j.ccr.2005.01.029 · DOI · Paper page
- Castellano, 2011, Functional specificity of ras isoforms: so similar but so different, Genes Cancer, 2, 216, 10.1177/1947601911408081 · DOI · Paper page
- Wennerberg, 2005, The Ras superfamily at a glance, J. Cell Sci., 118, 843, 10.1242/jcs.01660 · DOI · Paper page
- Furth, 1982, Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family, J. Virol., 43, 294, 10.1128/JVI.43.1.294-304.1982 · DOI · Paper page
- Lacal, 1986, Monoclonal-Antibody Y13-259 recognizes an epitope of the P21 ras molecule not directly involved in the Gtp-binding activity of the protein, Mol. Cell. Biol., 6, 1002, 10.1128/MCB.6.4.1002 · DOI
- Mulcahy, 1985, Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells, Nature (London), 313, 241, 10.1038/313241a0 · DOI · Paper page
- Cardinale, 1998, The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells, FEBS Lett., 439, 197, 10.1016/S0014-5793(98)01369-6 · DOI
- Shin, 2017, Antibody targeting intracellular oncogenic ras mutants exerts anti-tumour effects after systemic administration, Nat. Commun., 8, 15090, 10.1038/ncomms15090 · DOI
- Clark, 1985, Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding, Proc. Natl. Acad. Sci. U. S. A., 82, 5280, 10.1073/pnas.82.16.5280 · DOI · Paper page
- Feramisco, 1985, Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein, Nature, 314, 639, 10.1038/314639a0 · DOI
- Wong, 2012, A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3K-C2b) regulation, PLoS One, 7, e45360, 10.1371/journal.pone.0045360 · DOI
- Pai, 1989, Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation, Nature, 341, 209, 10.1038/341209a0 · DOI · Paper page
- Reiss, 1990, Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides, Cell, 62, 81, 10.1016/0092-8674(90)90242-7 · DOI · Paper page
- Lerner, 1995, Disruption of oncogenic K-Ras4b processing and signaling by a potent geranylgeranyltransferase-I inhibitor, J. Biol. Chem., 270, 26770, 10.1074/jbc.270.45.26770 · DOI · Paper page
- Whyte, 1997, K- N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem., 272, 14459, 10.1074/jbc.272.22.14459 · DOI · Paper page
- Novotny, 2017, Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K-Ras, ACS Chem. Biol., 12, 1956, 10.1021/acschembio.7b00374 · DOI · Paper page
- Rocks, 2005, An acylation cycle regulates localization and activity of palmitoylated ras isoforms, Science, 307, 1746, 10.1126/science.1105654 · DOI · Paper page
- Rocks, 2010, The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins, Cell, 141, 458, 10.1016/j.cell.2010.04.007 · DOI · Paper page
- Papke, 2016, Identification of pyrazolopyridazinones as PDEd inhibitors, Nat. Commun., 7, 11360, 10.1038/ncomms11360 · DOI · Paper page
- Martin-Gago, 2017, A PDE6delta-KRas inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2, Angew. Chem. Int. Ed. Engl., 56, 2423, 10.1002/anie.201610957 · DOI · Paper page
- Thompson, 2013, US National Cancer Institute's new Ras project targets an old foe, Nat. Med., 19, 949, 10.1038/nm0813-949 · DOI
- Ahmadian, 1999, Guanosine triphosphatase stimulation of oncogenic Ras mutants, Proc. Natl. Acad. Sci. U. S. A., 96, 7065, 10.1073/pnas.96.12.7065 · DOI · Paper page
- Patgiri, 2011, An orthosteric inhibitor of the Ras-Sos interaction, Nat. Chem. Biol., 7, 585, 10.1038/nchembio.612 · DOI · Paper page
- Leshchiner, 2015, Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices, Proc. Natl. Acad. Sci. U. S. A., 112, 1761, 10.1073/pnas.1413185112 · DOI · Paper page
- Wu, 2013, Inhibition of ras-effector interaction by cyclic peptides, Medchemcomm, 4, 378, 10.1039/C2MD20329D · DOI · Paper page
- Upadhyaya, 2015, Inhibition of ras signaling by blocking ras-effector interactions with cyclic peptides, Angew. Chem. Int. Ed. Engl., 54, 7602, 10.1002/anie.201502763 · DOI · Paper page
- Upadhyaya, 2016, Direct inhibitors of ras-effector protein interactions, Mini Rev. Med. Chem., 16, 376, 10.2174/1389557515666151001141713 · DOI
- Welsch, 2017, Multivalent small-molecule Pan-RAS inhibitors, Cell, 168, 878, 10.1016/j.cell.2017.02.006 · DOI · Paper page
- Forbes, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res., 43, D805, 10.1093/nar/gku1075 · DOI · Paper page
- Zhang, 2009, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer, 9, 28, 10.1038/nrc2559 · DOI · Paper page
- Feuerstein, 1987, Preparation and characterization of nucleotide-free and metal ion-free p21 apoprotein, J. Biol. Chem., 262, 8455, 10.1016/S0021-9258(18)47433-9 · DOI · Paper page
- Finkel, 1984, Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21, Cell, 37, 151, 10.1016/0092-8674(84)90310-6 · DOI
- Hattori, 1985, Biochemical-properties of a highly purified V-Rash P21 protein overproduced in Escherichia-Coli and inhibition of its activities by a monoclonal-antibody, Mol. Cell. Biol., 5, 1449, 10.1128/MCB.5.6.1449 · doi:10.1128/mcb.5.6.1449
- Wolin, 1996, Synthesis and evaluation of pyrazolo [3,4-b]quinoline ribofuranosides and their derivatives as inhibitors of oncogenic ras, Bioorg. Med. Chem. Lett., 6, 195, 10.1016/0960-894X(95)00574-D · doi:10.1016/0960-894x(95)00574-d
- Noonan, 1991, Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins, J. Med. Chem., 34, 1302, 10.1021/jm00108a010 · DOI
- Taveras, 1997, Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex, Bioorg. Med. Chem., 5, 125, 10.1016/S0968-0896(96)00202-7 · DOI
- Peri, 2005, Design, synthesis and biological evaluation of sugar-derived Ras inhibitors, Chembiochem, 6, 1839, 10.1002/cbic.200400420 · DOI · Paper page
- Muller, 2017, Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity, Sci. Rep., 7, 3687, 10.1038/s41598-017-03973-6 · DOI
- Tanaka, 2003, Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies, J. Mol. Biol., 331, 1109, 10.1016/S0022-2836(03)00836-2 · DOI
- Tanaka, 2010, Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth, Oncogene, 29, 6064, 10.1038/onc.2010.346 · DOI
- Tanaka, 2007, Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS, EMBO J., 26, 3250, 10.1038/sj.emboj.7601744 · DOI
- Choi, 2014, A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells, MAbs, 6, 1402, 10.4161/mabs.36389 · DOI
- Kim, 2015, Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells by an enhanced split GFP complementation assay, Biochem. Biophys. Res. Commun., 467, 771, 10.1016/j.bbrc.2015.10.066 · DOI
- Guillard, 2017, Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange, Nat. Commun., 8, 16111, 10.1038/ncomms16111 · DOI · Paper page
- Santos, 2014, Dimerization opens new avenues into Ras signaling research, Sci. Signal., 7, pe12, 10.1126/scisignal.2005318 · DOI
- Guldenhaupt, 2012, N-Ras forms dimers at POPC membranes, Biophys. J ., 103, 1585, 10.1016/j.bpj.2012.08.043 · DOI
- Lin, 2014, H-Ras forms dimers on membrane surfaces via a protein–protein interface, Proc. Natl. Acad. Sci. U. S. A., 111, 2996, 10.1073/pnas.1321155111 · DOI · Paper page
- Plowman, 2005, H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton, Proc. Natl. Acad. Sci. U. S. A., 102, 15500, 10.1073/pnas.0504114102 · DOI · Paper page
- Murakoshi, 2004, Single-molecule imaging analysis of ras activation in living cells, Proc. Natl. Acad. Sci. U. S. A., 101, 7317, 10.1073/pnas.0401354101 · DOI · Paper page
- Santos, 1988, Oligomeric structure of p21 ras proteins as determined by radiation inactivation, J. Biol. Chem., 263, 9853, 10.1016/S0021-9258(19)81595-8 · DOI
- Inouye, 2000, Formation of the ras dimer is essential for Raf-1 activation, J. Biol. Chem., 275, 3737, 10.1074/jbc.275.6.3737 · DOI · Paper page
- Tian, 2007, Plasma membrane nanoswitches generate high-fidelity ras signal transduction, Nat. Cell Biol., 9, 905, 10.1038/ncb1615 · DOI · Paper page
- Prior, 2003, Direct visualization of ras proteins in spatially distinct cell surface microdomains, J. Cell Biol., 160, 165, 10.1083/jcb.200209091 · DOI · Paper page
- Janosi, 2012, Organization, dynamics, and segregation of ras nanoclusters in membrane domains, Proc. Natl. Acad. Sci. U. S. A., 109, 8097, 10.1073/pnas.1200773109 · DOI · Paper page
- Janosi, 2010, Segregation of negatively charged phospholipids by the polycationic and farnesylated membrane anchor of Kras, Biophys. J ., 99, 3666, 10.1016/j.bpj.2010.10.031 · DOI
- Zhou, 2014, Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters, Mol. Cell. Biol., 34, 862, 10.1128/MCB.01227-13 · DOI · Paper page
- Kovrigina, 2015, The ras G domain lacks the intrinsic propensity to form dimers, Biophys. J ., 109, 1000, 10.1016/j.bpj.2015.07.020 · DOI
- Tian, 2010, Mathematical modeling of K-Ras nanocluster formation on the plasma membrane, Biophys. J ., 99, 534, 10.1016/j.bpj.2010.04.055 · DOI
- Freeman, 2013, The importance of Raf dimerization in cell signaling, Small GTPases, 4, 180, 10.4161/sgtp.26117 · DOI · Paper page
- Freeman, 2013, Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling, Mol. Cell, 49, 751, 10.1016/j.molcel.2012.12.018 · DOI · Paper page
- Hancock, 2003, Ras proteins: different signals from different locations, Nat. Rev. Mol. Cell Biol., 4, 373, 10.1038/nrm1105 · DOI · Paper page
- Cho, 2012, Raf inhibitors target ras spatiotemporal dynamics, Curr. Biol., 22, 945, 10.1016/j.cub.2012.03.067 · DOI
- Sha, 2017, Monobodies and other synthetic binding proteins for expanding protein science, Protein Sci., 26, 910, 10.1002/pro.3148 · DOI · Paper page
- Spencer-Smith, 2017, Targeting the α4-α5 interface of RAS results in multiple levels of inhibition, Small GTPases, 10.1080/21541248.2017.1333188 · DOI
- Gibbs, 1984, Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules, Proc. Natl. Acad. Sci. U. S. A., 81, 5704, 10.1073/pnas.81.18.5704 · DOI · Paper page
- Burtness, 2014, Trials, 15, 469, 10.1186/1745-6215-15-469 · DOI
Cited by
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
The current understanding of KRAS protein structure and dynamics
Pantsar, T. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.004 · Cited by 282
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
Pharmacological targeting of RAS: recent success with direct inhibitors
O’Bryan, J. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.021 · Cited by 153
“These findings provided the first direct evidence for the critical importance of the α4-α5 interface in RAS self-association and function and suggested that targeting this region may provide a new approach to inhibit RAS function [111].”
BackgroundSelf-citationCurrent therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
Sakamoto, K., Masutani, T., & Hirokawa, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78712-5 · Cited by 85
Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Khan, I., Spencer-Smith, R., & O’Bryan, J. P. (2019) · Oncogene · doi:10.1038/s41388-018-0636-y · Cited by 54
Self-citationTargeting Small GTPases and Their Prenylation in Diabetes Mellitus
Gendaszewska-Darmach, E., Garstka, M. A., & Błażewska, K. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00410 · Cited by 35
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Metadata
- Authors
- Spencer-Smith, R., & O’Bryan, J. P.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 54
- Pages
- 138-148
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2775445984
- Cited by
- 86
- References
- 30
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- NIH F31 Predoctoral Award (CA192822)
- United States (US) Department of Veterans Affairs Biomedical Laboratory Research and Development Service (1I01BX002095)
- NIH awards (CA201717, CA212608)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.